



RECEIVED

AUG 30 2002

SEQUENCE LISTING

TECH CENTER 1600/2900

<110> YU, XIANXHANG  
WAGNER, THOMAS E.

<120> THERAPEUTIC PORE-FORMING PEPTIDES

<130> 035879/0122

<140> 09/851,422

<141> 2001-05-09

<150> 60/203,063

<151> 2000-05-09

<150> 60/212,042

<151> 2000-06-16

<160> 12

<170> PatentIn Ver. 2.1

<210> 1

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<220>

<221> MOD\_RES

<222> (10)..(13)

<223> This region may be selected from the group consisting of [epsilon-gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon-alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]-(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.

<220>

<221> MOD\_RES

<222> (22)..(25)

<223> This region may be selected from the group consisting of [epsilon-gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon-alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]-(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.

<220>

<221> MOD\_RES

<222> (34)..(37)

<223> This region may be selected from the group consisting of [epsilon-gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon-alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]-(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.

<220>

<223> This molecule may encompass smaller embodiments according  
to the application as filed

31  
2

<400> 1  
Gly Phe Ile Ala Thr Leu Cys Thr Lys Xaa Xaa Xaa Xaa Val Leu Asp  
1 5 10 15

Phe Gly Ile Asp Lys Xaa Xaa Xaa Xaa Leu Ile Gln Leu Ile Glu Asp  
20 25 30

Lys Xaa Xaa Xaa Xaa  
35

<210> 2  
<211> 38  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

C1

<220>  
<221> MOD\_RES  
<222> (8)..(11)  
<223> This region may be selected from the group consisting of [epsilon-gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon-alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]-(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.

<220>  
<221> MOD\_RES  
<222> (26)..(29)  
<223> This region may be selected from the group consisting of [epsilon-gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon-alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]-(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.

<220>  
<221> MOD\_RES  
<222> (32)..(35)  
<223> This region may be selected from the group consisting of [epsilon-gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon-alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]-(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.

<220>  
<223> This molecule may encompass smaller embodiments according to the application as filed

<400> 2  
Gly Ile Gly Ala Val Leu Lys Xaa Xaa Xaa Xaa Val Leu Thr Thr Gly  
1 5 10 15

Leu Pro Ala Leu Ile Ser Trp Ile Lys Xaa Xaa Xaa Xaa Arg Lys Xaa  
20 25 30

Xaa Xaa Xaa Arg Gln Gln  
35

32  
/

<210> 3  
<211> 25  
<212> PRT  
<213> Entamoeba histolytica

<400> 3  
Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp  
1 5 10 15  
Lys Leu Ile Gln Leu Ile Glu Asp Lys  
20 25

<210> 4  
<211> 37  
<212> PRT  
<213> Antheraea pernyi

<220>  
<223> Cecropin A  
C1  
<400> 4  
Lys Trp Lys Leu Phe Lys Lys Ile Glu Lys Val Gly Gln Asn Ile Arg  
1 5 10 15  
Asp Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Val Gly Gln Ala  
20 25 30  
Thr Gln Ile Ala Lys  
35

<210> 5  
<211> 35  
<212> PRT  
<213> Antheraea pernyi

<220>  
<223> Cecropin B  
C1  
<400> 5  
Lys Trp Lys Ile Phe Lys Lys Ile Glu Lys Val Gly Arg Asn Ile Arg  
1 5 10 15  
Asn Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Leu Gly Glu Ala  
20 25 30  
Lys Ala Leu  
35

<210> 6  
<211> 36  
<212> PRT  
<213> Antheraea pernyi

35  
A

<220>  
<223> Cecropin D

<400> 6  
Trp Asn Pro Phe Lys Glu Leu Glu Lys Val Gly Gln Arg Val Arg Asp  
1 5 10 15  
Ala Val Ile Ser Ala Gly Pro Ala Val Ala Thr Val Ala Gln Ala Thr  
20 25 30  
Ala Leu Ala Lys  
35

<210> 7  
<211> 26  
<212> PRT  
<213> Apis mellifera

C1  
<400> 7  
Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu  
1 5 10 15  
Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln  
20 25

<210> 8  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MOD\_RES  
<222> (26)..(27)  
<223> [epsilon-gamma]-Glu-[alpha-gamma]-Glu

<400> 8  
Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp  
1 5 10 15  
Lys Leu Ile Gln Leu Ile Glu Asp Lys Xaa Xaa  
20 25

<210> 9  
<211> 26  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

34  
8

<220>  
<221> MOD\_RES  
<222> (26)  
<223> [epsilon-alpha]-Phe

<400> 9  
Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp  
1 5 10 15

Lys Leu Ile Gln Leu Ile Glu Asp Lys Xaa  
20 25

<210> 10  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<220>  
<221> MOD\_RES  
<222> (18)  
<223> [epsilon-alpha]-Phe

<220>  
<221> MOD\_RES  
<222> (27)  
<223> [epsilon-alpha]-Phe

<400> 10  
Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp  
1 5 10 15

Lys Xaa Leu Ile Gln Leu Ile Glu Asp Lys Xaa  
20 25

<210> 11  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<220>  
<221> MOD\_RES  
<222> (22)  
<223> [epsilon-gamma]-Glu

<220>  
<221> MOD\_RES

C1

35  
6

<222> (25)  
<223> [epsilon-gamma]-Glu

<400> 11  
Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu  
1 5 10 15

Ile Ser Trp Ile Lys Xaa Arg Lys Xaa Arg Gln Gln  
20 25

<210> 12  
<211> 30  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

C1  
<220>  
<221> MOD\_RES  
<222> (22)..(23)  
<223> [epsilon-gamma]-Glu-[alpha-gamma]-Glu

<220>  
<221> MOD\_RES  
<222> (26)..(27)  
<223> [epsilon-gamma]-Glu-[alpha-gamma]-Glu

<400> 12  
Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu  
1 5 10 15

Ile Ser Trp Ile Lys Xaa Xaa Arg Lys Xaa Xaa Arg Gln Gln  
20 25 30

---